One of the most important questions in obesity medicine: is the weight loss durable if you stop?
After a 36-week open-label lead-in on tirzepatide (during which participants lost roughly a fifth of body weight on average), SURMOUNT-4 randomized them either to continue tirzepatide or to switch to placebo for about another year, while all continued lifestyle counseling.
The continuation group maintained their loss and lost a little more, while the placebo group regained a substantial portion of the weight they had lost. The divergence was large and consistent with what is seen across the incretin drug class when treatment stops.
The trial reframes expectations: tirzepatide manages weight while it is being taken, much as blood-pressure medication manages blood pressure while taken. Stopping tends to be followed by regain because the underlying biology that defends higher weight is still present. This argues for planning treatment as long-term, not as a short course.
If treatment is often long-term, the recurring monthly cost matters more than any introductory price. That is why we emphasize maintenance-dose pricing and annualized cost in the Price Index. Discuss duration, goals and an exit or maintenance strategy with your clinician.
Individual results vary, and some people maintain better than others. The trial used the branded product; compounded tirzepatide is not FDA-approved. Decisions about stopping should be made with a clinician.
The clearest practical implication of SURMOUNT-4 is that tirzepatide should usually be planned as ongoing treatment, not a short course — much like medication for blood pressure or cholesterol, which work while taken and lose effect when stopped. That reframing has real consequences: it shifts the relevant cost from any introductory price to the recurring monthly price you will pay for as long as treatment continues, and it makes a provider's long-term pricing structure and cancellation terms central rather than incidental. It also means conversations about stopping deserve a deliberate plan — tapering where appropriate, intensifying lifestyle support, and monitoring — rather than an abrupt halt. None of this implies anyone is “stuck” on the drug; some people do maintain after stopping, and goals legitimately change. But expecting effortless maintenance after discontinuation runs against the evidence, and planning around the biology tends to produce better, less discouraging outcomes than treating regain as a surprise or a personal failing.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
In SURMOUNT-4, people who switched to placebo regained a large share of the weight they had lost, while those who continued maintained their loss.
The evidence suggests obesity is chronic and that weight loss is best maintained with ongoing treatment, much like other chronic-disease medications.
Not necessarily all, but substantial regain is common without continued treatment or another sustained intervention. Plan stopping with a clinician.